Alkem Laboratories Limited, an Indian multinational pharmaceutical company, has signed a license agreement with Harvard University's Office of Technology Development enabling Alkem to develop and commercialize a novel technology that may help meet the dire need for effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.
The deep ocean – dark, cold, under high pressure, and airless – is notoriously inhospitable to humans, yet it teems with organisms that manage to thrive…